蒸気圧
<0.1 mmHg ( 20 °C)
アッセイ
99.97%
フォーム
foil
メーカー／製品名
Goodfellow 538-687-18
抵抗性
129 μΩ-cm, 20°C
サイズ×厚み
50x50 mm × 0.015 mm
bp
1560 °C (lit.)
mp
271 °C (lit.)
密度
9.8 g/mL at 25 °C (lit.)
SMILES記法
[Bi]
InChI
1S/Bi
InChI Key
JCXGWMGPZLAOME-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
For updated SDS information please visit www.goodfellow.com.
法的情報
Goodfellow製品
最新バージョンのいずれかを選択してください：
Hong Lu et al.
European journal of gastroenterology & hepatology, 25(10), 1134-1140 (2013-06-20)
Antimicrobial resistance has continued to undermine many popular anti-Helicobacter pylori therapies. Antibiotic resistance to commonly used anti-H. pylori drugs in China has increased markedly, making China an ideal site to identify regimens that remain effective despite widespread antimicrobial resistance. Bismuth
Jorge A R Salvador et al.
Molecules (Basel, Switzerland), 16(4), 2884-2913 (2011-04-06)
Steroid and terpene chemistry still have a great impact on medicinal chemistry. Therefore, the development of new reactions or "greener" processes in this field is a contemporaneous issue. In this review, the use of bismuth(III) salts, as "ecofriendly" reagents/catalysts, on
Ruiguang Ge et al.
Metallomics : integrated biometal science, 4(3), 239-243 (2012-02-24)
Helicobacter pylori causes various gastric diseases, such as gastritis, peptic ulcerations and gastric cancer. Bismuth-based triple or quadruple therapies have been commonly recommended for the treatment of H. pylori infections. Up to now, the molecular mechanisms by which bismuth inhibits
Jorge A R Salvador et al.
Future medicinal chemistry, 4(11), 1495-1523 (2012-08-04)
In recent years, the chemical potential of bismuth and bismuth compounds has been actively exploited. Bismuth salts are known for their low toxicity, making them potential valuable reagents for large-scale synthesis, which becomes more obvious when dealing with products such
P Moayyedi et al.
Alimentary pharmacology & therapeutics, 17(10), 1215-1227 (2003-05-21)
Evidence for the effectiveness of antacids, histamine-2 receptor antagonists, bismuth salts, sucralfate and prokinetic therapy in non-ulcer dyspepsia is conflicting. To conduct a systematic review evaluating these therapies in non-ulcer dyspepsia. Electronic searches were performed using the Cochrane Controlled Trials
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
